ASX-Dividend-Report-Banner

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

December 05, 2024 07:33 PM AEDT | By Cision
 Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments
Image source: Kalkine Media

- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth attracted over 500 visitors.

- Educated over 300 Thai physicians on the innovative "Nabolift" technique through the "Nabota Master Class (NMC)."

- Established its position as a premium global brand with proven "efficacy" and "quality."

BANGKOK, Thailand, Dec. 5, 2024 /PRNewswire/ -- Daewoong Pharmaceutical has captured the attention of global aesthetic medicine professionals with its innovative botulinum toxin treatment techniques.

On November 20, medical professionals attending the 'Nabota Master Class (NMC)' held in Bangkok, Thailand, posed for a commemorative photo.
On November 20, medical professionals attending the 'Nabota Master Class (NMC)' held in Bangkok, Thailand, posed for a commemorative photo.

Daewoong Pharmaceutical (CEO Seong-su Park, Chang-jae Lee) announced on December 5 that it participated in the Aesthetic & Anti-Aging Medicine World Congress in Southeast Asia 2024 (AMWC SEA), held from November 21 to 23 in Bangkok, Thailand. The company shared Nabota's outstanding quality and cutting-edge medical aesthetic techniques with global healthcare professionals.

AMWC is one of the top three aesthetic medicine congresses in the world, bringing together global experts and companies to share the latest advancements in aesthetic medicine. This year's event in Thailand welcomed over 1,200 medical professionals and 50 companies.

At the event, Daewoong introduced its distinctive botulinum toxin treatment method, "Nabolift." The Nabota booth drew significant interest, with more than 500 healthcare professionals visiting. During symposium lectures, Daewoong highlighted how the Nabolift method effectively improves wrinkles, skin elasticity, and skin texture, garnering enthusiastic responses from participants.

In a symposium session focusing on Nabolift, Dr. Goo Boncheol of Naeum Dermatology in Korea presented techniques for enhancing skin elasticity and texture in the lower face, including the neck and jawline, using Nabota. Thai dermatologist Dr. Sasathorn Singthong also shared her experiences with Nabolift and its growing trends in Thailand, attracting considerable interest from the audience.

Dr. Goo commented, "Nabota's rapid and precise effects allow physicians to accurately determine dosages and injection points, enabling tailored results for each patient. It was truly meaningful to share Korea's expertise and innovations with global medical professionals who are passionate about K-beauty."

Dr. Singthong added, "In Thailand, Gen Z increasingly values natural beauty. Micro-injections of botulinum toxin to improve wrinkles and skin elasticity are becoming more popular. Nabota, with its proven quality and efficacy, has  gained the trust of Thai physicians, offering natural and satisfying results."

Before AMWC, Daewoong hosted the "Nabota Master Class (NMC)" at Benchakitti Hospital in Bangkok on November 20. The event gathered over 300 Thai medical professionals and featured lectures, live demonstrations, and clinical case discussions on Nabota-based treatments.

The first session, titled "Nabolift Techniques for Wrinkle and Skin Elasticity Improvement," included theoretical lectures, followed by a live hands-on session where Thai dermatologists demonstrated the Nabolift technique. Participants had the opportunity to practice the techniques themselves, expressing high satisfaction with learning Korea's advanced and innovative botulinum toxin treatment methods and global trends.

Nabota is expected to achieve sales of THB 276 million in Thailand this year. Competing with over 10 brands in the Thai market, Nabota's success is attributed to its proven efficacy and quality, renowned globally in markets such as the U.S. and Europe. After receiving FDA approval in the U.S. and EMA approval in Europe in 2019, Daewoong's botulinum toxin has expanded to 80 countries worldwide and is classified as a premium product. Particularly in the U.S., Nabota has gained significant popularity, capturing a 13% share of the American aesthetics market this year and ranking second, surpassing major global competitors.

Jun-Soo Yun, Head of Daewoong's Nabota Business Division, stated, "We have solidified Nabota's position as a premium brand in Thailand, a leader in the Southeast Asian aesthetic market. We will continue to share Nabota's unique and differentiated techniques with healthcare professionals worldwide, further strengthening our position as a global medical aesthetics leader."


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.